MitoPark mice mirror the slow progression of key symptoms and L-DOPA response in Parkinson's disease
- PMID: 20002202
- PMCID: PMC4154513
- DOI: 10.1111/j.1601-183X.2009.00542.x
MitoPark mice mirror the slow progression of key symptoms and L-DOPA response in Parkinson's disease
Abstract
The MitoPark mouse, in which the mitochondrial transcription factor Tfam is selectively removed in midbrain dopamine (DA) neurons, is a genetic model for Parkinson's disease (PD) that replicates the slow and progressive development of key symptoms. To further validate this model, we have extended both behavioral and biochemical analyses in these animals. We found that vertical movements decline earlier and faster than horizontal movements, possibly modeling the early occurrence of axial, postural instability in PD. L-DOPA induces different locomotor responses depending on the age: in young MitoPark mice the L-DOPA-induced motor activation is small; middle-aged MitoPark mice respond in a dose-dependent manner to L-DOPA, whereas aged MitoPark mice display a double-peaked locomotor response to a high dose of L-DOPA that includes an intermittent period of very low motor activity, similar to the 'on-off' phenomenon in PD. To correlate behavior with biochemical data, we analyzed monoamine levels in three different brain areas that are highly innervated by the DA system: striatum, anterior cortex and olfactory bulb. DA levels declined earlier and faster in striatum than in cortex; only at the latest time-point analyzed, DA levels were found to be significantly lower than control levels in the olfactory bulb. Interestingly, the ratio between homovanillic acid (HVA) and DA differed between regions over time. In striatum and olfactory bulb, the ratio increased steeply indicating increased DA turnover. In contrast, the ratio decreased over time in cortex, revealing important differences between DA cells in substantia nigra and the ventral tegmental area.
Conflict of interest statement
Conflict of interest statement: N- G. L. and L. O. are co-owners of a company owning commercial rights to the MitoPark mice.
Figures






Similar articles
-
L-Dopa induced dyskinesias in Parkinsonian mice: Disease severity or L-Dopa history.Brain Res. 2015 Aug 27;1618:261-9. doi: 10.1016/j.brainres.2015.06.005. Epub 2015 Jun 16. Brain Res. 2015. PMID: 26086365 Free PMC article.
-
Loss of dopamine disrupts circadian rhythms in a mouse model of Parkinson's disease.Neurobiol Dis. 2014 Nov;71:359-69. doi: 10.1016/j.nbd.2014.08.024. Epub 2014 Aug 27. Neurobiol Dis. 2014. PMID: 25171792
-
Chronic L-DOPA induces hyperactivity, normalization of gait and dyskinetic behavior in MitoPark mice.Genes Brain Behav. 2015 Mar;14(3):260-70. doi: 10.1111/gbb.12210. Genes Brain Behav. 2015. PMID: 25752644 Free PMC article.
-
The MitoPark Mouse - an animal model of Parkinson's disease with impaired respiratory chain function in dopamine neurons.Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S185-8. doi: 10.1016/S1353-8020(09)70811-9. Parkinsonism Relat Disord. 2009. PMID: 20082987 Review.
-
Progressive parkinsonism due to mitochondrial impairment: Lessons from the MitoPark mouse model.Exp Neurol. 2021 Jul;341:113707. doi: 10.1016/j.expneurol.2021.113707. Epub 2021 Mar 20. Exp Neurol. 2021. PMID: 33753138 Free PMC article. Review.
Cited by
-
Mitochondrial Dysfunction: A Key Player in Brain Aging and Diseases.Curr Issues Mol Biol. 2024 Mar 2;46(3):1987-2026. doi: 10.3390/cimb46030130. Curr Issues Mol Biol. 2024. PMID: 38534746 Free PMC article. Review.
-
Neurological Phenotypes in Mouse Models of Mitochondrial Disease and Relevance to Human Neuropathology.Int J Mol Sci. 2023 Jun 2;24(11):9698. doi: 10.3390/ijms24119698. Int J Mol Sci. 2023. PMID: 37298649 Free PMC article. Review.
-
Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson's Disease.ACS Pharmacol Transl Sci. 2021 Mar 16;4(2):858-869. doi: 10.1021/acsptsci.1c00013. eCollection 2021 Apr 9. ACS Pharmacol Transl Sci. 2021. PMID: 33860208 Free PMC article.
-
Targeting mitophagy in Parkinson's disease.J Biol Chem. 2021 Jan-Jun;296:100209. doi: 10.1074/jbc.REV120.014294. Epub 2020 Dec 24. J Biol Chem. 2021. PMID: 33372898 Free PMC article. Review.
-
Usp14 down-regulation corrects sleep and circadian dysfunction of a Drosophila model of Parkinson's disease.Front Neurosci. 2024 Aug 5;18:1410139. doi: 10.3389/fnins.2024.1410139. eCollection 2024. Front Neurosci. 2024. PMID: 39161651 Free PMC article.
References
-
- Chiodo LA, Bannon MJ, Grace AA, Roth RH, Bunney BS. Evidence for the absence of impulse-regulating somato-dendritic and synthesis-modulating nerve terminal autoreceptors on subpopulations of mesocortical DA neurons. Neuroscience. 1984;12:1–16. - PubMed
-
- Coyle JT. The development of catecholaminergic neurons of the central nervous system. Neurosci Res. 1973;5:35–52. - PubMed
-
- Ekstrand M, Larsson NG. Breeding and genotyping of Tfam conditional knockout mice. Methods Mol Biol. 2002;197:391–400. - PubMed
-
- Ekstrand M, Terzioglu M, Galter D, Zhu S, Hofstetter C, Lindqvist E, Thams S, Bergstrand A, Hansson FS, Trifunovic A, Hoffer B, Cullheim S, Mohammed AH, Olson L, Larsson NG. Progressive parkinsonism in mice with respiratory-chain-deficient DA neurons. Proc Natl Acad Sci U S A. 2007;104:1325–1330. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases